Elm3 Financial Group LLC Acquires New Holdings in Amgen Inc. $AMGN

07 Oct 2026, 20:56 by Teresa Graham · The Cerbat Gem

Elm3 Financial Group LLC bought a new stake in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) in the third quarter, Holdings Channel reports. The institutional investor bought 1,259 shares of the medical research company’s stock, valued at approximately $531,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of AMGN. State Street Corp increased its holdings in shares of Amgen by 38.2% in the 2nd quarter. State Street Corp now owns 42,205,243 shares of the medical research company’s stock worth $15,283,363,000 after buying an additional 11,656,755 shares during the last quarter. Bank of America Corp DE purchased a new stake in Amgen during the second quarter valued at approximately $1,831,903,000. Wellington Management Group LLP lifted its stake in shares of Amgen by 1,102.7% in the 2nd quarter. Wellington Management Group LLP now owns 2,742,271 shares of the medical research company’s stock valued at $993,031,000 after purchasing an additional 2,514,254 shares during the last quarter. BlackRock Inc. boosted its holdings in shares of Amgen by 4.8% in the 2nd quarter. BlackRock Inc. now owns 49,362,016 shares of the medical research company’s stock worth $17,874,974,000 after purchasing an additional 2,261,544 shares during the period. Finally, Corient Private Wealth LP bought a new position in shares of Amgen during the 2nd quarter valued at approximately $187,401,000. 76.50% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages have recently weighed in on AMGN. UBS Group reissued a “buy” rating and issued a $430.00 target price on shares of Amgen in a research note on Thursday, September 17th. Bank of America increased their price objective on shares of Amgen from $312.00 to $317.00 and gave the stock an “underperform” rating in a research report on Wednesday, August 5th. Mizuho raised their price target on Amgen from $303.00 to $352.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 18th. BMO Capital Markets downgraded Amgen from an “outperform” rating to a “market perform” rating and set a $450.00 price objective on the stock. in a research report on Tuesday, September 8th. Finally, Weiss Ratings upgraded Amgen from a “buy (b-)” rating to a “buy (b)” rating in a research report on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, sixteen have given a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $385.79.

Read Our Latest Stock Analysis on Amgen

Amgen Stock Up 2.6%

NASDAQ:AMGN traded up $10.48 during mid-day trading on Wednesday, reaching $413.08. The company’s stock had a trading volume of 2,236,544 shares, compared to its average volume of 2,758,837. The company has a quick ratio of 1.13, a current ratio of 1.37 and a debt-to-equity ratio of 4.44. Amgen Inc. has a 1 year low of $288.00 and a 1 year high of $447.03. The stock has a fifty day moving average of $411.95 and a 200-day moving average of $371.46. The firm has a market capitalization of $223.32 billion, a PE ratio of 25.67, a price-to-earnings-growth ratio of 2.91 and a beta of 0.41.

Amgen (NASDAQ:AMGN – Get Free Report) last posted its earnings results on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, beating analysts’ consensus estimates of $5.62 by $0.67. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The business had revenue of $10.05 billion for the quarter, compared to the consensus estimate of $9.43 billion. During the same quarter last year, the firm posted $6.02 EPS. The company’s revenue for the quarter was up 9.5% on a year-over-year basis. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Equities research analysts forecast that Amgen Inc. will post 22.94 earnings per share for the current year.

Amgen Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 11th. Investors of record on Friday, August 21st were issued a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a yield of 2.4%. The ex-dividend date of this dividend was Friday, August 21st. Amgen’s dividend payout ratio (DPR) is presently 62.65%.

Trending Headlines about Amgen

Here are the key news stories impacting Amgen this week:

Positive Sentiment: Amgen reported results from a clinical trial involving a treatment for Sjögren’s disease. The update appears to have supported the stock by providing investors with additional visibility into the company’s immunology pipeline. Amgen announces Sjogren’s trial results
Positive Sentiment: Amgen participated in Arboretum LifeSciences’ $30 million Series A financing. The investment could give Amgen access to AI-driven genetic testing and molecular-data capabilities that may improve precision-medicine decisions and the design of genomically targeted clinical trials. Amgen backs Arboretum LifeSciences Series A
Positive Sentiment: Amgen’s AMG 513 obesity study reached Phase 1 completion. While early-stage completion does not establish efficacy, the program adds another potential growth opportunity as the company competes in the weight-loss drug market. Amgen AMG 513 obesity trial update
Neutral Sentiment: Cantor Fitzgerald maintained a Neutral rating, while another report cited a Neutral rating with a $400 price target. These views suggest analysts see limited near-term upside after the recent advance. Cantor Fitzgerald maintains Neutral rating
Neutral Sentiment: A former Amgen commercial leader joined Entera Bio, a move relevant to Entera rather than Amgen and unlikely to materially affect AMGN’s fundamentals. Former Amgen leader joins Entera
Negative Sentiment: Morgan Stanley lowered its price target to $359 while maintaining an Equal Weight rating, and Truist raised its target to $380 but kept a Hold rating. Both targets remain below the current share price, signaling valuation concerns and potential downside. Morgan Stanley lowers Amgen price target Truist raises Amgen price target

Insider Buying and Selling

In other news, SVP Rachna Khosla sold 2,000 shares of Amgen stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $412.57, for a total value of $825,140.00. Following the transaction, the senior vice president directly owned 6,404 shares in the company, valued at approximately $2,642,098.28. This trade represents a 23.80% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Nancy A. Grygiel sold 2,970 shares of the business’s stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $402.16, for a total value of $1,194,415.20. Following the completion of the transaction, the senior vice president directly owned 7,340 shares of the company’s stock, valued at approximately $2,951,854.40. The trade was a 28.81% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 6,222 shares of company stock valued at $2,540,926 in the last three months. 0.85% of the stock is currently owned by insiders.

Amgen Profile

(Free Report)

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research and commercial activities focus on areas including oncology, cardiovascular disease, inflammation, bone health, neuroscience and rare diseases. The company uses biologic research, human genetics and other advanced technologies to develop targeted therapies and supports patients through treatment and disease-management services.

Amgen’s portfolio includes medicines such as Enbrel for inflammatory diseases; Prolia and Evenity for osteoporosis; Xgeva for cancer-related bone complications; Repatha for certain cardiovascular conditions; Otezla for inflammatory diseases; Aimovig for migraine prevention; Tezspire for severe asthma; and Lumakras for certain cancers.